Experience with second-line trabectedin in daily clinical practice: case studies

As a recommended second-line option for advanced soft tissue sarcoma, trabectedin can provide the necessary balance between long-term tumor control and preserved quality of life. Three case studies illustrate the long-lasting responses that patients can achieve with second-line trabectedin. A female...

Full description

Saved in:
Bibliographic Details
Published inFuture oncology (London, England) Vol. 18; no. 30s; pp. 23 - 32
Main Authors Martín-Broto, Javier, Hindi, Nadia, Grignani, Giovanni, Merlini, Alessandra, Ibrahim, Tony, Le Cesne, Axel
Format Journal Article
LanguageEnglish
Published Future Medicine Ltd 01.09.2022
Subjects
advanced leiomyosarcoma
growth modulation index
long responder
myxoid/round cell liposarcoma
soft tissue sarcoma
solitary fibrous tumor
trabectedin
Online AccessGet full text

Cover

More Information
Summary:As a recommended second-line option for advanced soft tissue sarcoma, trabectedin can provide the necessary balance between long-term tumor control and preserved quality of life. Three case studies illustrate the long-lasting responses that patients can achieve with second-line trabectedin. A female patient with metastatic leiomyosarcoma maintained disease control for 2 years with trabectedin (× 41 cycles) with excellent tolerability and no relevant adverse events. At the time of writing, a male patient with a metastatic solitary fibrous tumor was asymptomatic after 30 cycles of trabectedin and treatment was ongoing. A young male patient with a recurrent, nonresectable, retroperitoneal myxoid/round cell liposarcoma was able to continue his sporting activities (triathlons) over 2 years with trabectedin (× 14 cycles) plus watchful waiting.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1479-6694
1744-8301
DOI:10.2217/fon-2022-0519